BAZ2A Biomarker Predicts Prostate Cancer Malignancy

BAZ2A Biomarker Predicts Prostate Cancer Malignancy
shutterstock_88457716 (1)Findings from the "Early Onset Prostate Cancer" project, conducted by a collaboration among the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and many others, show that a key serum biomarker indicates the aggressiveness of prostate cancer. The protein is involved in epigenetic maintenance of tumor cells and is directly associated with prostate cancer malignancy, a central concern to patients and physicians. It has been known that genetic alterations indicate how dangerous prostate cancer can be but, relative to other cancer types, few mutations exist in prostate tumors. "We therefore suspected that prostate cancer is driven primarily by alterations in epigenetic characteristics, that is, chemical changes in the genetic material that do not affect the sequence of DNA building blocks," said Professor Christoph Plass, of the German Cancer Research Center, in a press release from the center. Epigenetic changes refer to DNA modifications beyond those resulting from mutations. Although much is known about the possible types of epigenetic changes, little is known about how cancer cells undergo epigenetic changes of DNA. The group of sc
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *